09Apr 2025
Lesion Size Predicts Survival in mRCC Immunotherapy Patients

Lesion Size Predicts Survival in mRCC Immunotherapy Patients

The study of 99 patients found that those with maximal evaluable lesion size (MLS) ≥35 mm had significantly worse progression-free and overall survival. Karnofsky performance status <80%, non-clear cell histology, and large MLS independently predicted outcomes. A new prognostic model using these factors stratifies mRCC patients effectively for nivolumab plus ipilimumab treatment.

  • #urology

Like

Save

Share